SCHEMBL832024

SCHEMBL832024

Cc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(C)(=O)=O)n2Cc1cc(C#N)ccc1F

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.41
KMT2A Q03164 2/20 0.35
PTGDR2 Q9Y5Y4 7/20 0.34
CNR1 P21554 2/20 0.33
PPARG P37231 1/20 0.33
ALOX5AP P20292 1/20 0.33
PARP14 Q460N5 1/20 0.32
CXCR2 P25025 2/20 0.32
PTGS1 P23219 1/20 0.31
SCN2B O60939 1/20 0.31
SCN1B Q07699 1/20 0.31
SCN5A Q14524 1/20 0.31
SCN9A Q15858 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862259 0.92 CYP2C8 (0.42) CYP2C8KMT2APTGDR2CNR1PPARG
SCHEMBL831269 0.91 CYP2C8 (0.38) CYP2C8KMT2APPARGALOX5APPARP14
SCHEMBL831826 0.91 CYP2C8 (0.39) CYP2C8KMT2APTGDR2CNR1PARP14
SCHEMBL831198 0.90 CYP2C8 (0.43) CYP2C8KMT2APTGDR2PPARGSCN2B
SCHEMBL831922 0.88 CYP2C8 (0.42) CYP2C8KMT2APTGDR2PPARGPTGS1
SCHEMBL831577 0.88 CYP2C8 (0.46) CYP2C8KMT2APTGDR2PPARGSCN2B
SCHEMBL831364 0.88 CYP2C8 (0.45) CYP2C8KMT2APTGDR2PPARGPTGS1
SCHEMBL862102 0.87 CYP2C8 (0.42) CYP2C8KMT2APTGDR2CNR1PPARG
SCHEMBL831797 0.87 CYP2C8 (0.41) CYP2C8KMT2APTGDR2PPARGPTGS1
SCHEMBL831753 0.86 CYP2C8 (0.41) CYP2C8KMT2APTGDR2PPARGSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885PTGDR2 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.